サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1655380

鉄剤の世界市場

Iron Drugs

出版日
ページ情報
英文 187 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
鉄剤の世界市場
出版日: 2025年02月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

鉄剤の世界市場は2030年までに110億米ドルに達する見込み

2024年に69億米ドルと推定される鉄剤の世界市場は、分析期間2024-2030年にCAGR 7.9%で成長し、2030年には110億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである経口剤は、CAGR 9.2%を記録し、分析期間終了時には67億米ドルに達すると予測されます。点滴薬セグメントは、分析期間中のCAGRが6.1%と推定されます。

米国市場は18億米ドルと推定、中国はCAGR 11.9％で成長予測

米国の鉄剤市場は2024年に18億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに28億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.9%と7.1%と予測されています。欧州では、ドイツがCAGR 4.8%で成長すると予測されています。

世界の鉄剤市場- 主要動向と戦略的洞察

鉄欠乏症の治療に鉄剤が欠かせない理由とは？

鉄剤は、鉄欠乏性貧血（IDA）など、鉄の補給が必要な鉄欠乏症の治療において重要な役割を果たしています。鉄欠乏性貧血（IDA）をはじめ、鉄の補給が必要な疾患では、鉄欠乏性貧血治療薬（鉄剤）が重要な役割を担っています。鉄欠乏症は、不十分な食事摂取、慢性的な出血、吸収不良症候群など様々な原因によって起こるため、鉄剤は様々な患者集団における治療プロトコルの重要な要素となっています。鉄剤がヘモグロビン値を改善し、疲労や脱力感などの症状を緩和するのに有効であることは、臨床における鉄剤の重要性を強調しています。

新しい製剤はどのように鉄剤の有効性を高めていますか？

鉄剤の製剤における最近の進歩は、その有効性と忍容性を高め、従来の鉄サプリメントの限界のいくつかに対処しています。例えば、多糖類-鉄複合体製剤やヘム鉄ポリペプチド製剤の開発により、消化管での鉄の吸収が改善され、硫酸第一鉄のような旧来の鉄塩にありがちな消化器系の副作用が軽減されています。さらに、カルボキシマルトース鉄剤やスクロース鉄剤などの静脈注射用鉄剤のイントロダクションは、特に重度の貧血患者や経口鉄剤に耐えられない患者に対して、より迅速かつ効率的に鉄を補給する手段を提供しています。これらの新しい製剤は、ヘルスケア提供者が利用できる治療選択肢の幅を広げ、鉄欠乏症のより個別化された効果的な管理を可能にしています。

鉄剤治療にはどのような課題があり、どのように対処しているのか？

鉄剤治療は効果的ではあるが、課題がないわけではないです。最も一般的な問題の一つは、経口鉄剤に伴う胃腸の不快感で、これは患者のアドヒアランス不良につながります。この問題に対処するため、より忍容性の高い新しい製剤が開発されており、患者には、食事と一緒にサプリメントを摂取するなど、副作用を最小限に抑える方法が教育されています。もう一つの課題は、特に長期治療を受けている患者やヘモクロマトーシスのような疾患を持つ患者における鉄過剰症のリスクです。このリスクを軽減するためには、鉄レベルを注意深くモニターし、個別に投与戦略を立てることが不可欠です。さらに、新しい静脈内鉄製剤のコストと入手可能性は、特に低資源環境では、一部の患者にとって障壁となりうる。このような課題を克服するためには、手頃な価格の鉄療法へのアクセスを向上させ、医療従事者にベストプラクティスを教育する取り組みが不可欠です。

鉄剤市場の成長を促進する要因は？

鉄剤市場の成長は、鉄欠乏症や関連疾患の有病率の増加、新規製剤や改良製剤の開発、新興国におけるヘルスケアインフラの拡大など、いくつかの要因によって牽引されています。貧血の世界の負担が特に女性、子供、高齢者の間で増加し続けているため、効果的な鉄療法への需要が高まっています。また、吸収が良く、副作用が少なく、より早く効果が得られる先進的な製剤のイントロダクションも、より効果的な治療選択肢を提供することで市場の成長を後押ししています。さらに、鉄欠乏症の早期診断・早期治療の重要性に対する認識の高まりと発展途上地域におけるヘルスケアサービスの拡大が、鉄剤の利用を増加させています。より多くのヘルスケアプロバイダーがこれらの新しい治療法を採用し、患者が選択肢についてより多くの情報を得るようになるにつれて、鉄剤市場は上昇基調を続けると予想されます。

セグメント

製品（経口薬、点滴薬）

調査対象企業の例（注目の28社）

  • Allergan, Inc.
  • AMAG Pharmaceuticals, Inc.
  • American Regent, Inc.
  • Daiichi Sankyo Company, Ltd.
  • Fresenius Medical Care AG & Co.
  • Nippon Shinyaku Co., Ltd
  • Pharmacosmos A/S
  • Rockwell Medical Technologies, Inc.
  • Sanofi
  • Shield Therapeutics Plc
  • Vifor Pharma Management Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP12864

Global Iron Drugs Market to Reach US$11.0 Billion by 2030

The global market for Iron Drugs estimated at US$6.9 Billion in the year 2024, is expected to reach US$11.0 Billion by 2030, growing at a CAGR of 7.9% over the analysis period 2024-2030. Oral Drugs, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$6.7 Billion by the end of the analysis period. Growth in the IV Drugs segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 11.9% CAGR

The Iron Drugs market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 11.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Iron Drugs Market - Key Trends & Strategic Insights

Why Are Iron Drugs Essential in Treating Iron Deficiency Disorders?

Iron drugs play a critical role in the treatment of iron deficiency disorders, including iron deficiency anemia (IDA) and other conditions where iron supplementation is necessary. These drugs are used to replenish the body's iron stores, enabling the production of hemoglobin and the proper functioning of red blood cells. Iron deficiency can result from various causes, such as inadequate dietary intake, chronic blood loss, or malabsorption syndromes, making iron drugs a key component of treatment protocols across different patient populations. The effectiveness of iron drugs in improving hemoglobin levels and alleviating symptoms such as fatigue and weakness underscores their importance in clinical practice.

How Are New Formulations Enhancing the Efficacy of Iron Drugs?

Recent advancements in iron drug formulations are enhancing their efficacy and tolerability, addressing some of the limitations of traditional iron supplements. For example, the development of polysaccharide-iron complex and heme iron polypeptide formulations has improved the absorption of iron in the gastrointestinal tract, reducing the gastrointestinal side effects that are common with older iron salts like ferrous sulfate. Additionally, the introduction of intravenous (IV) iron preparations, such as ferric carboxymaltose and iron sucrose, offers a faster and more efficient means of replenishing iron stores, particularly in patients with severe anemia or those who cannot tolerate oral iron. These new formulations are expanding the range of treatment options available to healthcare providers, allowing for more personalized and effective management of iron deficiency.

What Challenges Are Associated with Iron Drug Therapy, and How Are They Being Addressed?

Iron drug therapy, while effective, is not without challenges. One of the most common issues is the gastrointestinal discomfort associated with oral iron supplements, which can lead to poor patient adherence. To address this, newer formulations with better tolerability are being developed, and patients are being educated on how to minimize side effects, such as by taking supplements with food. Another challenge is the risk of iron overload, particularly in patients receiving long-term therapy or those with conditions like hemochromatosis. Careful monitoring of iron levels and individualized dosing strategies are essential to mitigate this risk. Additionally, the cost and availability of newer IV iron formulations can be a barrier for some patients, particularly in low-resource settings. Efforts to increase access to affordable iron therapies and educate healthcare providers on best practices are crucial to overcoming these challenges.

Which Factors Are Propelling the Growth of the Iron Drugs Market?

The growth of the iron drugs market is driven by several factors, including the increasing prevalence of iron deficiency and related disorders, the development of new and improved formulations, and the expansion of healthcare infrastructure in emerging markets. As the global burden of anemia continues to rise, particularly among women, children, and the elderly, the demand for effective iron therapies is growing. The introduction of advanced formulations that offer better absorption, fewer side effects, and faster results is also driving market growth by providing more effective treatment options. Additionally, the growing awareness of the importance of early diagnosis and treatment of iron deficiency, coupled with the expansion of healthcare services in developing regions, is increasing the uptake of iron drugs. As more healthcare providers adopt these newer therapies and as patients become more informed about their options, the iron drugs market is expected to continue its upward trajectory.

SCOPE OF STUDY:

The report analyzes the Iron Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Oral Drugs, IV Drugs)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 28 Featured) -

  • Allergan, Inc.
  • AMAG Pharmaceuticals, Inc.
  • American Regent, Inc.
  • Daiichi Sankyo Company, Ltd.
  • Fresenius Medical Care AG & Co.
  • Nippon Shinyaku Co., Ltd
  • Pharmacosmos A/S
  • Rockwell Medical Technologies, Inc.
  • Sanofi
  • Shield Therapeutics Plc
  • Vifor Pharma Management Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Iron Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Oral Iron Formulations Propel Innovation in Iron Drug Therapies
    • Growing Demand for Intravenous (IV) Iron Drugs Expands Addressable Market
    • Shift Towards Targeted Drug Delivery Strengthens Business Case for New Iron Drugs
    • Increased Focus on Treating Chronic Kidney Disease (CKD) Drives Adoption of Iron Drugs
    • Technological Innovations in Sustained-Release Formulations Accelerate Market Growth
    • Rising Awareness of Iron Deficiency in Women Throws Spotlight on Iron Drugs
    • Expanding Applications of Iron Drugs in Pediatric Populations Generate New Opportunities
    • Shift Towards Safer and Better-Tolerated Iron Drugs Drives Market Innovation
    • Rising Concerns About Gastrointestinal Side Effects Strengthen Demand for Improved Iron Drugs
    • Expansion of Iron Drugs in Oncology Care Accelerates Market Growth
    • Growing Emphasis on Nutritional Support in Anemia Management Sustains Demand for Iron Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Iron Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Oral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for IV Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for IV Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for IV Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: USA 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: Canada 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • JAPAN
    • Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: Japan 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • CHINA
    • Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: China 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • EUROPE
    • Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Europe 15-Year Perspective for Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • FRANCE
    • Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: France 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • GERMANY
    • Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Germany 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Italy 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: UK 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Spain 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Russia 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Iron Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Iron Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 15-Year Perspective for Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Australia 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • INDIA
    • Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: India 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: South Korea 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Iron Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Iron Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Latin America 15-Year Perspective for Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Latin America 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Argentina 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Brazil 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Mexico 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Iron Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Iron Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Middle East 15-Year Perspective for Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Middle East 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Iran 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Israel 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UAE 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030
  • AFRICA
    • Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Iron Drugs by Product - Oral Drugs and IV Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Iron Drugs by Product - Oral Drugs and IV Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Africa 15-Year Perspective for Iron Drugs by Product - Percentage Breakdown of Value Sales for Oral Drugs and IV Drugs for the Years 2015, 2025 & 2030

IV. COMPETITION